Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery
Participants must have histologically or cytologically confirmed disease from any solid tumor
Participants must have histologically or cytologically confirmed disease from any solid tumor
Participants must have histologically or cytologically confirmed low- to intermediate-grade neuroendocrine tumor (carcinoid tumor)
Part A and Part B: Has histologically or cytologically-confirmed metastatic solid tumor.
Patients must have histologically confirmed solid tumor that is metastatic or unresectable, and there is no available therapy likely to convey clinical benefit.
Patients with a histologically or cytologically confirmed solid tumor malignancy
Histologically or cytologically confirmed unresectable or medically inoperable malignant pleural mesothelioma
Patients must have histologically confirmed solid tumor that is metastatic or unresectable, and there is no available therapy likely to convey clinical benefit
For enrollment into the NTRK cohort: participants must have a histologically or cytologically confirmed advanced solid tumor and must have received at least one prior line of therapy in the metastatic setting
Diagnosed with histologically confirmed solid tumor located in the peripheral lung
Histologically or cytologically confirmed diagnosis of an advanced, malignant, solid tumor(s) with all standard treatment options having been exhausted or declined.
Subjects must have histologically confirmed solid malignancy that is metastatic or unresectable
PHASE I: Histologically confirmed solid tumor malignancy
Participants must have histologically confirmed malignant tumor
COHORT B, GROUP : MESOTHELIOMA: Patients must have histologically or cytologically proven diagnosis of malignant mesothelioma; both pleural and peritoneal mesothelioma are allowed
Patients must have histologically or cytologically confirmed any solid tumor (cohort ) or prostate cancer (cohort ); no prior treatment other than testosterone lowering therapy for mCRPC is required
Histologically or cytologically confirmed solid tumor cancer
Arm A -patients expansion cohort: patients with histologically or cytologically proven chemotherapy naive unresectable malignant pleural or peritoneal mesothelioma
Patients must have histologically or cytologically confirmed solid organ malignancy
Patients must have histologically or cytologically confirmed progressive advanced or metastatic solid tumor of one of the following:
Histologically or cytologically confirmed pleural malignant mesothelioma, epithelial or biphasic subtypes
Has a histologically or cytologically confirmed diagnosis of a solid tumor malignancy (except for any excluded malignancies listed in the Exclusion Criteria) that is not responsive to standard therapy(ies) or for which there is no approved therapy.
Histologically confirmed epithelioid predominantly (> %) subtype malignant pleural mesothelioma
Patients must have histologically or cytologically confirmed malignant pleural mesothelioma (MPM)
Histologically confirmed malignant extra-cranial solid tumor or desmoid fibromatosis.
Histologically documented diagnosis of solid tumor
Histologically or cytologically confirmed diagnosis of solid malignant tumor.
Has a histologically- or cytologically-confirmed metastatic solid tumor for which there is no available therapy which may convey clinical benefit. Part E: Has advanced malignant melanoma.
Phase Ib: Patient must have histologically or cytologically documented solid tumor malignancies
Patients must have histologically confirmed solid malignancy or lymphoma that is metastatic or unresectable
Histologically confirmed malignant solid tumor and not a candidate for known regimens or protocol treatments of higher efficacy or priority
Patients must have histologically and/or cytologically confirmed solid tumors or B cell lymphoma that are metastatic or unresectable and for which standard treatment options do not exist; patients with hepatocellular carcinoma are eligible without pathological diagnosis if diagnosed on the basis of blood work and imaging
Histologically confirmed solid tumor (leukemia and lymphoma are excluded)
Histologically- or cytologically- confirmed solid tumor (except melanoma) that is\n             metastatic or unresectable
Patient must have histologically or cytologically confirmed diagnosis of malignant pleural mesothelioma; surgical resection must not be planned
Histologically or cytologically confirmed diagnosis of malignancy with demonstrated progression of a solid tumor (non-lymphoma) with no alternative standard-of-care therapeutic option (certain exceptions may apply).
For the phase I portion, patients must have histologically and/or cytologically confirmed malignant solid tumor that is refractory to standard therapies
Histologically confirmed solid tumor malignancy with greater than  sites of metastatic disease detected on cross-sectional imaging
Subject must have histologically or cytologically confirmed solid tumor;
Subjects must have histologically or cytologically confirmed advanced solid tumor for recurrent or metastatic disease.
Patients must have a histologically confirmed or highly suspected (as determined by treating physician) solid tumor that is planned for surgical resection
Malignant pleural mesothelioma (histologically confirmed epithelial)
Patients must have histologically confirmed diagnosis of unresectable malignant pleural mesothelioma
Histologically or cytologically confirmed pleural or peritoneal malignant mesothelioma, epithelial, sarcomatoid, or biphasic subtypes
Patients with histologically or cytologically confirmed solid malignancy are eligible for treatment as long as insurance approval for docetaxel is obtained
A histologically confirmed solid tumor of the gastrointestinal tract including
Histologically confirmed malignant pleural mesothelioma that is not metastatic or unresectable
Histologically or cytologically confirmed malignant pleural or peritoneal mesothelioma (MPM)
Patients must have a histologically confirmed diagnosis of epithelioid, sarcomatoid, or mixed-type malignant pleural or peritoneal mesothelioma that is not amenable to surgery
Phase Ia: Patients must have histologically or cytologically documented metastatic solid tumor malignancies
Patients must have a histologically or cytologically confirmed metastatic solid tumor malignancy for the phase I component; the phase II component will require patients to have histologically or cytologically confirmed non-small cell lung carcinoma regardless of histology
Histologically or cytologically confirmed solid tumor.
Part A Subjects with histologically or cytologically confirmed malignant advanced solid tumors, who have progressed on at least  prior chemotherapy, and for whom either
Histologically or cytologically confirmed diagnosis of solid tumor malignancy that is not responsive to standard therapies or for which there is no approved or curative therapy.
Have a histologically or cytologically confirmed diagnosis of advanced solid tumor or lymphoma, or primitive hepatocarcinoma with radiological diagnosis
Histologically or cytologically confirmed diagnosis of a solid tumor.
Histologically or cytologically confirmed diagnosis of solid tumor in advanced stage which taxane-based therapy is a rational treatment option.
Patients must have a histologically confirmed solid tumor that is considered incurable and is not amenable to conventional surgical, radiation therapy or chemotherapy treatment programs
Patients with a histologically and/or cytologically confirmed solid tumor who are resistant / refractory to approved therapies or for whom no curative therapies are available
Histologically or cytologically confirmed diagnosis of solid malignancy
Patients with a histologically or cytologically confirmed solid tumor or aggressive NHL who are refractory to or have exhausted all available therapies
Participants must have histologically or cytologically confirmed diagnosis of solid tumor malignancy, lymphoma, or multiple myeloma
Participants must have histologically confirmed diagnosis of a solid tumor for which no curative therapy exists
Patients who are scheduled to receive a taxane-based regimen for a histologically confirmed solid tumor that is:
For Parts A and B: Has histologically or cytologically confirmed metastatic solid tumor
Somatostatin receptor  positive tumor as assessed at pre-screening or within  d of first drug administration using indium SPECT or gallium PET Patients in Phase  must have a histologically or cytologically-confirmed solid tumor in  of the following categories:
Patients with a histologically confirmed solid tumor:
